9d • General discussion
CAGRILINTIDE
What is Cagrilintide?
Cagrilintide (also known as AM833/NNC0174-0833) is a long-acting synthetic amylin analogue and
dual amylin/calcitonin receptor agonist (DACRA). It mimics the hormone amylin, which is co-secreted
with insulin and helps regulate appetite and slow gastric emptying — mechanisms that support weight
control and metabolic health.
It is being developed for weight management and type 2 diabetes, and has been studied alone and in
combination with GLP-1 receptor agonists (e.g., semaglutide) under names like CagriSema.
Benefits:
1. Appetite Suppression and Satiety
Cagrilintide activates amylin pathways in the brain helping you feel fuller, reduce hunger signals, and
eat less overall.
2. Weight Loss
In trials:
● As monotherapy, it produces significant weight reduction.
● In combination with semaglutide (CagriSema), mean weight loss up to ~22.7% has been
reported, a very high efficacy among obesity meds.
3. Metabolic Improvements
Studies show better glycemic control (lower HbA1c) and improvements in metabolic markers like
triglycerides and insulin sensitivity.
4. Convenient Dosing
Once-weekly subcutaneous injections make it easy to integrate into regimens similar to GLP-1
therapies.
Dosing:
Because cagrilintide is not FDA-approved yet, dosing schedules vary across clinical studies. The
common theme is gradual weekly titration to help reduce side effects. If using a GLP, dose Cagrilintide 2-3 days after your GLP injection.
A typical dose escalation in trials looked like:
● Weeks 1–4: ~0.25–0.3 mg/week
● Weeks 5–8: ~0.5–0.6 mg/week
● Weeks 9–12: ~1.0–1.2 mg/week
● Weeks 13–16: ~1.7–2.4 mg/week
● Maintenance: ~2.4 mg/week (some trials explored up to 4.5 mg)
Maximum doses in research did not exceed ~4.5 mg/week.
Combination with Semaglutide (CagriSema)
Clinical trial protocols often matched cagrilintide titration with semaglutide escalation:
● Cagrilintide → 0.6 → 1.2 → 1.8 → 2.4 mg weekly
● Semaglutide → 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly
Both reach full therapeutic dose around week 16–17.
Administration Notes
● Route: Subcutaneous injection (abdomen, thigh, or upper arm)
● Frequency: Once weekly, same day each week
● Slow Titration: Critical to help mitigate nausea and GI side effects
Safety and Side Effects
Common side effects in trials and research include:
✔ Mild to moderate nausea and vomiting
✔ Early satiety or fullness
✔ Constipation or GI discomfort
These tend to be dose-related and mostly transient, often decreasing as the body adjusts.
Since it slows gastric emptying, caution is advised in people with pre-existing GI disorders. Clinical
cautions also include theoretical concerns in individuals with certain endocrine tumors or severe renal
impairment.
6
13 comments
CAGRILINTIDE
skool.com/kristinas-peptide-junkies-24-4251
Advance your peptide research with precise, science-driven guidance, expert community talk, and access to vetted suppliers, promotions, and giveaways.
Leaderboard (30-day)
1
+7
2
+5
3
+4
4
+3
5
+3
Powered by